Esperion Strikes Licensing Agreement with Neopharm
Esperion Therapeutics (NASDAQ: ESPR) recently announced a significant licensing agreement with Neopharm Israel. This exclusive partnership will allow Neopharm to commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Israel. Esperion will receive an upfront payment along with milestone payments and tiered royalties based on sales performance in the region.
Partnership Goals
The aim of this collaboration is clear: to improve cardiovascular health among millions of Israelis at risk for heart disease. According to Efi Shnaidman, the CEO of Neopharm, the partnership represents a shared commitment to delivering these important therapeutic options to patients. With a successful history of launching pharmaceutical products for over 80 years, Neopharm possesses the expertise necessary to establish NEXLETOL and NEXLIZET in the Israeli market.
Agreement Details
As part of the licensing deal, Neopharm will obtain exclusive rights to market NEXLETOL and NEXLIZET in Israel, along with rights in the Gaza Strip and West Bank. Shortly after the agreement is finalized, Esperion will receive an upfront payment, followed by an additional payment linked to marketing approval and inclusion in the National Healthcare Reimbursement Basket. Furthermore, the agreement stipulates that Esperion will earn royalties on sales generated in the specified territory.
Therapeutic Indications
NEXLIZET and NEXLETOL are recognized for their cardiovascular benefits. NEXLETOL is indicated for adults unable to take statins and who have either established cardiovascular disease or are at high risk for such events. On the other hand, NEXLIZET serves as an adjunct therapy for reducing LDL-C in adults with primary hyperlipidemia.
Safety Information for Patients
Patients considering NEXLIZET and NEXLETOL should be aware of the important safety information associated with these medications. Contraindications include previous hypersensitivity to the components of the drugs. Potential serious reactions can include allergic responses such as anaphylaxis. Bempedoic acid, found in both therapies, may increase uric acid levels, leading to gout in some cases, necessitating periodic monitoring of uric acid levels.
Common Adverse Reactions
In clinical trials, adverse reactions were reported in more than 2% of patients. These included upper respiratory tract infections, muscle spasms, and increased liver enzymes. Due to the risk of tendon rupture, discontinuation of NEXLIZET or NEXLETOL is recommended at the first sign of tendon injury, particularly in older patients or those with previous tendon issues.
About Neopharm Israel
Neopharm Israel, founded in 1941, is a premier player in the Israeli pharmaceutical sector. With a robust history of successful product launches and market access, the company has become a trusted partner for multinational pharmaceutical firms looking to enter or grow within the Israeli market. Its extensive portfolio and ongoing developments contribute significantly to healthcare.
About Esperion Therapeutics
Esperion is dedicated to discovering, developing, and commercializing innovative therapies aimed at improving health outcomes for patients susceptible to cardiovascular and cardiometabolic diseases. The organization is focused on addressing the unmet health needs of individuals with high cholesterol by providing effective treatments to help them achieve their LDL-C goals.
Frequently Asked Questions
What is NEXLETOL and what does it treat?
NEXLETOL is a medication used to lower LDL cholesterol in individuals who are unable to take statin therapy, particularly in patients with cardiovascular risks.
Who is Neopharm Israel?
Neopharm Israel is a leading pharmaceutical company with over 80 years of experience in commercializing various pharmaceutical products within Israel.
What are the safety considerations for NEXLETOL?
Patients should monitor for hypersensitivity reactions and significant increases in uric acid levels while taking NEXLETOL.
How will the agreement benefit patients?
This partnership aims to provide innovative cardiovascular treatments to patients in Israel, ultimately improving their health outcomes and accessibility to medications.
What role does Esperion play in this partnership?
Esperion is responsible for providing the product and receiving tiered royalties, while Neopharm will manage the commercialization within Israel.
